SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Psychiatry Northwest, LLC, one of the fastest growing transcranial magnetic stimulation (TMS) practices in the Pacific Northwest, announced today that it is offering BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) treatment to patients suffering from Obsessive-Compulsive Disorder (OCD) in its TMS Washington facility. BrainsWay's Deep TMS technology is not only the first medical device to be cleared by the FDA for the treatment of OCD, but it is also the first TMS system developed for multiple indications. Psychiatry Northwest has been providing BrainsWay's Deep TMS therapy for the treatment of depression to its patients since 2016.
"Psychiatry Northwest is constantly in search of the latest innovations in TMS healing, committed to providing the best-in-class treatment to our patients," said Dr. Jesse McClelland, Medical Director of Psychiatry Northwest. "A constant struggle for those suffering from OCD is difficulty tolerating medications and treatment resistance. The prospect of treating OCD non-invasively, without requiring hospitalization or anesthesia and with minimal systemic side effects is revolutionary. BrainsWay's OCD treatment will no doubt advance the way we treat OCD in the United States. We are proud that we are now able to provide advanced Deep TMS treatment to both OCD and depression patients."
TMS Washington treatment center is advancing new horizons in TMS therapy with Deep TMS, attracting patients from around the globe. In anticipation of the high demand for BrainsWay's latest treatment, Psychiatry Northwest is incorporating two OCD devices to service its patients without delays, avoiding any capacity issues. The facility will also offer affordable self-pay OCD packages, including discounts on the first 100 TMS patient packages (29 treatments) purchased.
BrainsWay's Deep TMS technology sends magnetic pulses into deep structures of the anterior cingulate cortex, the region of the brain that is known to be involved in OCD. The treatment has no systemic side effects, allowing patients to continue with their daily activities immediately following treatment.
About BrainsWayBrainsWay Ltd./ BrainsWay USA, is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company's device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013, and is now FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD). The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.
About Psychiatry Northwest Psychiatry Northwest, TMS Washington's parent company, is a Gold Sponsor of the Washington State Psychiatry Association (WSPA), and is a leading specialty provider in the Pacific Northwest of adult and child ADD/ADHD, Treatment Resistant Depression and OCD. The practice has expanded rapidly since its establishment by Dr. McClelland in 2015. It employs state-of-the-art testing, treatment devices and protocols from around the globe and the practice will soon offer services seven days a week to its very large population of patients. TMS Washington was formed to integrate TMS treatment into our practice as the evolving science for treatment of our major specialties is evolving rapidly.
Psychiatry Northwest Media Contact:Richard Chiem[email protected]206-582-2010
BrainsWay Media Contact: Nechama Feuerstein [email protected]201-373-2228
Advertisement
"Psychiatry Northwest is constantly in search of the latest innovations in TMS healing, committed to providing the best-in-class treatment to our patients," said Dr. Jesse McClelland, Medical Director of Psychiatry Northwest. "A constant struggle for those suffering from OCD is difficulty tolerating medications and treatment resistance. The prospect of treating OCD non-invasively, without requiring hospitalization or anesthesia and with minimal systemic side effects is revolutionary. BrainsWay's OCD treatment will no doubt advance the way we treat OCD in the United States. We are proud that we are now able to provide advanced Deep TMS treatment to both OCD and depression patients."
Advertisement
TMS Washington treatment center is advancing new horizons in TMS therapy with Deep TMS, attracting patients from around the globe. In anticipation of the high demand for BrainsWay's latest treatment, Psychiatry Northwest is incorporating two OCD devices to service its patients without delays, avoiding any capacity issues. The facility will also offer affordable self-pay OCD packages, including discounts on the first 100 TMS patient packages (29 treatments) purchased.
BrainsWay's Deep TMS technology sends magnetic pulses into deep structures of the anterior cingulate cortex, the region of the brain that is known to be involved in OCD. The treatment has no systemic side effects, allowing patients to continue with their daily activities immediately following treatment.
About BrainsWayBrainsWay Ltd./ BrainsWay USA, is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company's device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013, and is now FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD). The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.
About Psychiatry Northwest Psychiatry Northwest, TMS Washington's parent company, is a Gold Sponsor of the Washington State Psychiatry Association (WSPA), and is a leading specialty provider in the Pacific Northwest of adult and child ADD/ADHD, Treatment Resistant Depression and OCD. The practice has expanded rapidly since its establishment by Dr. McClelland in 2015. It employs state-of-the-art testing, treatment devices and protocols from around the globe and the practice will soon offer services seven days a week to its very large population of patients. TMS Washington was formed to integrate TMS treatment into our practice as the evolving science for treatment of our major specialties is evolving rapidly.
Psychiatry Northwest Media Contact:Richard Chiem[email protected]206-582-2010
BrainsWay Media Contact: Nechama Feuerstein [email protected]201-373-2228
View original content:http://www.prnewswire.com/news-releases/psychiatry-northwest-now-offering-deep-transcranial-magnetic-stimulation-deep-tms-for-the-treatment-of-obsessive-compulsive-disorder-ocd-300746156.html
SOURCE Psychiatry Northwest
